- PR Newswire•8 days agoOncoSec to Host Investor & Analyst Day on November 17, 2016 Spotlighting Industry-Leading Intratumoral Immunotherapy Pipeline and Next Generation Research and Device Development
SAN DIEGO, Oct. 18, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that it will ...
- Investopedia•9 days ago
Oncology drugs have the potential to disrupt the cancer drug market. One analyst says this drugmaker has 176% upside from Friday's closing price.
- PR Newswire•13 days ago
SAN DIEGO, Oct. 13, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial ...
OncoSec Medical Incorporated (ONCS)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||1.75 x 1100|
|Ask||1.78 x 100|
|Day's Range||1.74 - 1.80|
|52wk Range||1.36 - 4.45|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-1.09|
|Avg Vol (3m)||118,518|
|Dividend & Yield||N/A (N/A)|